Meet Paul Tran, Founder and CEO of Rocketship DTC Brand MANSCAPED™
13.4.2021 16:00:00 EEST | Business Wire | Press release
Today, MANSCAPED™, the global leader in men’s below-the-waist grooming, is cracking the code behind the company’s success with an exclusive introduction to its Founder and CEO, Paul Tran. From early beginnings to ongoing endeavors, Paul maintains a steadfast dedication to creativity, long-term thinking, and lifelong learning. These are just a few key takeaways as we get acquainted with the man leading MANSCAPED’s massive movement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005280/en/
Paul Tran founded MANSCAPED in 2016 with a mission of moving men forward all over the world. (Photo: Business Wire)
A Born Entrepreneur. Born in Vietnam, Paul grew up with little, but with a big outlook on life. Although he experienced adversity at a young age, and as a first-generation immigrant in America who didn’t speak English, he reflects on his upbringing very fondly. Having nothing and coming from nothing ingrained a sense of ambition in Paul, driving him to make the most of any opportunity and practice empathy always.
After settling in New York, his vocabulary soon expanded beyond “hi” and, albeit the only Asian kid in school, he assimilated quickly among his peers and made friends due to his unassuming demeanor, self-awareness, and good nature. A born entrepreneur, Paul recalls one of his earliest memories from elementary school was when he hosted a raffle every Friday. It was a basic concept with no more than nickels on the table, but a weekly activity his classmates raved about and looked forward to. The popular game enhanced their lives unknowingly, while reaffirming Paul’s inner creative spirit.
Fast forward several years, this undeniable self-starter put himself through college at the University of Southern California where he studied at Marshall School of Business and Viterbi School of Engineering. He parlayed his education into his next ventures, which included launching and selling multiple businesses. One was a revolutionary science-backed skincare brand that provides a non-surgical solution for wrinkles and stretch marks. This was Paul’s first company that tackled taboos in the beauty space, but it most certainly wouldn’t be the last.
The MANSCAPED Movement. Paul launched MANSCAPED in 2016 with a vision of driving the movement that changes the face of men’s grooming. By focusing on the needs of what has, for too long, been a sensitive and often stigmatized subject, MANSCAPED has successfully untapped a vast market of male consumers. The brand not only provides premium tools and products for proper grooming but moves men forward by unlocking their confidence and allowing them to be the best versions of themselves. Paul lives by this mission every single day and envisions a world in the future where MANSCAPED plays a significant part in people’s lives all over the world.
Beyond seeing this vision materialize in real life, Paul thrives on working with his supportive and talented team. He is humble at his core, often highlighting teammates for execution and successes rather than taking any credit. This level of humility is understated but significant, as it flows deep into the organization. As CEO, Paul’s responsibilities are many. He loves overseeing the brand’s innovation and technology as a superior technician himself. He also spearheads the company’s direction as a brilliant strategist and constantly works to further establish MANSCAPED as an employer brand that puts company culture and people first. Ensuring that everyone feels valued, included, and appreciated for their efforts is extremely important to him.
Although at the helm of the entire MANSCAPED Family, Paul is a self-described introvert at heart and enjoys spending time in small groups where we can have meaningful conversations and directly care for his colleagues. His intelligent presentations, inspiring words, and witty humor are experienced by all 150 employees during MANSCAPED’s biweekly company-wide meetings. Calendar notifications go from mundane reminders to sparks of joy on these days. As a winner of Inc. Magazine’s Best Workplaces in 2020, MANSCAPED is a workforce of individuals who are as happy as they are grateful for the environment Paul has created.
A Philanthropic Future. When he gets a sliver of time outside of MANSCAPED, Paul feeds his soul by spending time with his wife and two young children. This dedicated father and loving husband shares a special intellectual curiosity with his family. When their conversations run the gamut, Paul always walks away with a fresh perspective on life and appreciation for how far he has come. His deep-rooted desire to give back and commitment to social responsibility are fundamentals he has brought to MANSCAPED, as well as beliefs he lives by. Just one of his lifelong philanthropic goals is setting up his own foundation to help orphans and underprivileged children in Vietnam, which will be a full circle moment for him and so many others he’s impacted along the way.
About MANSCAPED™:
Founded by Paul Tran in 2016, San Diego, California-based MANSCAPED is the global leader in men's grooming and hygiene below-the-waist. The product range includes only the best tools, formulations, and accessories for a simple, effective, and elevated male grooming routine. MANSCAPED offers a one-stop-shop at manscaped.com and direct-to-consumer shipping in more than 30 countries, spanning the United States, Canada, Australia, New Zealand, the United Kingdom, the European Union, Norway, and Switzerland. Select products and unique bundles can also be found on Amazon with Prime and pickup options available. Retail placement includes Target and Best Buy locations throughout the U.S., with further domestic and international retailers coming soon. For more information, visit the website or follow on Facebook, Instagram, Twitter, TikTok, YouTube, and Triller.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005280/en/
Contact information
Allison Frazier, Director of Public Relations – MANSCAPED, Inc.
allison@manscaped.com
925-216-2791
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
